期刊文献+
共找到2,429篇文章
< 1 2 122 >
每页显示 20 50 100
Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma 被引量:3
1
作者 Kun-Peng Ma Jin-Xin Fu +1 位作者 Feng Duan Mao-Qiang Wang 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第4期1236-1247,共12页
BACKGROUND The efficacy and safety of transarterial chemoembolization(TACE)combined with lenvatinib plus programmed cell death protein-1(PD-1)for unresectable hepato-cellular carcinoma(HCC)have rarely been evaluated a... BACKGROUND The efficacy and safety of transarterial chemoembolization(TACE)combined with lenvatinib plus programmed cell death protein-1(PD-1)for unresectable hepato-cellular carcinoma(HCC)have rarely been evaluated and it is unknown which factors are related to efficacy.AIM To evaluate the efficacy and independent predictive factors of TACE combined with lenvatinib plus PD-1 inhibitors for unresectable HCC.METHODS This study retrospectively enrolled patients with unresectable HCC who received TACE/lenvatinib/PD-1 treatment between March 2019 and April 2022.Overall survival(OS)and progression-free survival(PFS)were determined.The objective response rate(ORR)and disease control rate(DCR)were evaluated in accordance with the modified Response Evaluation Criteria in Solid Tumors.Additionally,the prognostic factors affecting the clinical outcome were assessed.RESULTS One hundred and two patients were enrolled with a median follow-up duration of 12.63 months.The median OS was 26.43 months(95%CI:17.00-35.87),and the median PFS was 10.07 months(95%CI:8.50-11.65).The ORR and DCR were 61.76%and 81.37%,respectively.The patients with Barcelona Clinic Liver Cancer Classification(BCLC)B stage,early neutrophil-to-lymphocyte ratio(NLR)response(decrease),or early alpha-fetoprotein(AFP)response(decrease>20%)had superior OS and PFS than their counterparts.CONCLUSION This study showed that TACE/lenvatinib/PD-1 treatment was well tolerated with encouraging efficacy in patients with unresectable HCC.The patients with BCLC B-stage disease with early NLR response(decrease)and early AFP response(decrease>20%)may achieve better clinical outcomes with this triple therapy. 展开更多
关键词 Transarterial chemoembolization EFFICACY Lenvatinib programmed cell death protein-1 inhibitors Unresectable hepatocellular carcinoma
下载PDF
Cytokine release syndrome triggered by programmed death 1 blockade(sintilimab)therapy in a psoriasis patient:A case report 被引量:1
2
作者 Ming-Hui Zhou Min-Feng Ye +2 位作者 Zhen-Xing Zhang Feng Tao Yu Zhang 《World Journal of Clinical Cases》 SCIE 2024年第18期3555-3560,共6页
BACKGROUND In recent years,immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy across diverse malignancies.Notably,in patients with advanced gastric cancer,the use of programmed death 1(PD-1)blocka... BACKGROUND In recent years,immune checkpoint inhibitors(ICIs)have demonstrated remarkable efficacy across diverse malignancies.Notably,in patients with advanced gastric cancer,the use of programmed death 1(PD-1)blockade has significantly prolonged overall survival,marking a pivotal advancement comparable to the impact of Herceptin over the past two decades.While the therapeutic benefits of ICIs are evident,the increasing use of immunotherapy has led to an increase in immune-related adverse events.CASE SUMMARY This article presents the case of a patient with advanced gastric cancer and chronic plaque psoriasis.Following sintilimab therapy,the patient developed severe rashes accompanied by cytokine release syndrome(CRS).Fortunately,effective management was achieved through the administration of glucocorticoid,tocilizumab,and acitretin,which resulted in favorable outcomes.CONCLUSION Glucocorticoid and tocilizumab therapy was effective in managing CRS after PD-1 blockade therapy for gastric cancer in a patient with chronic plaque psoriasis. 展开更多
关键词 Cytokine release syndrome programmed death 1 blockade Sintilimab PSORIASIS Gastric cancer Case report
下载PDF
Unresectable hepatocellular carcinoma:Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach
3
作者 Fei-Yu Zhao Dong-Yu Wang Nian-Song Qian 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第10期4042-4044,共3页
In this editorial,we review the article“Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carc... In this editorial,we review the article“Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma”.We specifically focused on whether transarterial chemoembolization combined with lenvatinib in combination with a programmed death 1 inhibitor could be used in patients with unresectable hepatocellular carcinoma.Since both transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 inhibitors play an important role in the treatment of advanced liver cancer,but the combination of all three therapeutic approaches needs more research. 展开更多
关键词 Transarterial chemoembolization programmed death 1 Lenvatinib Hepatocellular carcinoma
下载PDF
Assessment of programmed death-ligand 1 expression in primary tumors and paired lymph node metastases of gastric adenocarcinoma
4
作者 Brendha Cação Coimbra Marina Alessandra Pereira +4 位作者 Leonardo Cardili Venancio Avancini Ferreira Alves Evandro Sobroza de Mello Ulysses Ribeiro Jr Marcus Fernando Kodama Pertille Ramos 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第3期883-893,共11页
BACKGROUND Anti-programmed death-1/programmed death-ligand 1(PD-1/PD-L1)immuno-therapy has demonstrated promising results on gastric cancer(GC).However,PD-L1 can express differently between metastatic sites and primar... BACKGROUND Anti-programmed death-1/programmed death-ligand 1(PD-1/PD-L1)immuno-therapy has demonstrated promising results on gastric cancer(GC).However,PD-L1 can express differently between metastatic sites and primary tumors(PT).AIM To compare PD-L1 status in PT and matched lymph node metastases(LNM)of GC patients and to determine the correlation between the PD-L1 status and clinicopathological characteristics.METHODS We retrospectively reviewed 284 GC patients who underwent D2-gastrectomy.PD-L1 was evaluated by immunohistochemistry(clone SP142)using the com-bined positive score.All PD-L1+PT staged as pN+were also tested for PD-L1 expression in their LNM.PD-L1(-)GC with pN+served as the comparison group.RESULTS Among 284 GC patients included,45 had PD-L1+PT and 24 of them had pN+.For comparison,44 PD-L1(-)cases with pN+were included(sample loss of 4 cases).Of the PD-L1+PT,54.2%(13/24 cases)were also PD-L1+in the LNM.Regarding PD-L1(-)PT,9.1%(4/44)had PD-L1+in the LNM.The agreement between PT and LNM had a kappa value of 0.483.Larger tumor size and moderate/severe peritumoral inflammatory response were associated with PD-L1 positivity in both sites.There was no statistical difference in overall survival for PT and LNM according to the PD-L1 status(P=0.166 and P=0.837,respectively).CONCLUSION Intra-patient heterogeneity in PD-L1 expression was observed between the PT and matched LNM.This disagreement in PD-L1 status may emphasize the importance of considering different tumor sites for analyses to select patients for immunotherapy. 展开更多
关键词 Gastric cancer Lymph node programmed death ligand 1 Stomach neoplasms IMMUNOHISTOCHEMISTRY METASTASIS
下载PDF
Roles of the tumor microenvironment in the resistance to programmed cell death protein 1 inhibitors in patients with gastric cancer
5
作者 Ren-Jie Xia Xiao-Yu Du +5 位作者 Li-Wen Shen Jian-Guo Ma Shu-Mei Xu Rui-Fang Fan Jian-Wei Qin Long Yan 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第9期3820-3831,共12页
Despite the continuous developments and advancements in the treatment of gastric cancer(GC),which is one of the most prevalent types of cancer in China,the overall survival is still poor for most patients with advance... Despite the continuous developments and advancements in the treatment of gastric cancer(GC),which is one of the most prevalent types of cancer in China,the overall survival is still poor for most patients with advanced GC.In recent years,with the progress in tumor immunology research,attention has shifted toward immunotherapy as a therapeutic approach for GC.Programmed cell death protein 1(PD-1)inhibitors,as novel immunosuppressive medications,have been widely utilized in the treatment of GC.However,many patients are still resistant to PD-1 inhibitors and experience recurrence in the advanced stages of PD-1 immunotherapy.To reduce the occurrence of drug resistance and recurrence in GC patients receiving PD-1 immunotherapy,to maximize the clinical activity of immunosuppressive drugs,and to elicit a lasting immune response,it is essential to research the tumor microenvironment mechanisms leading to PD-1 inhibitor resistance in GC patients.This article reviews the progress in studying the factors influencing the resistance to PD-1 inhibitors in the GC tumor microenvironment,aiming to provide insights and a basis for reducing resistance to PD-1 inhibitors for GC patients in the future. 展开更多
关键词 Gastric cancer Tumor microenvironment programmed cell death protein 1 IMMUNOTHERAPY Drug resistance
下载PDF
Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1
6
作者 Shin Woo Kang Sung Hee Lim +5 位作者 Min-Ji Kim Jeeyun Lee Young Suk Park Ho Yeong Lim Won Ki Kang Seung Tae Kim 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第8期3521-3528,共8页
BACKGROUND Bevacizumab,an anti-vascular endothelial growth factor(VEGF)monoclonal antibody,inhibits angiogenesis and reduces tumor growth.Serum VEGF-C,lactate dehydrogenase,and inflammatory markers have been reported ... BACKGROUND Bevacizumab,an anti-vascular endothelial growth factor(VEGF)monoclonal antibody,inhibits angiogenesis and reduces tumor growth.Serum VEGF-C,lactate dehydrogenase,and inflammatory markers have been reported as predictive markers related to bevacizumab treatment.Programmed cell death ligand 1(PD-L1)could act upon VEGF receptor 2 to induce cancer cell angiogenesis and metastasis.AIM To investigate the efficacy of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer(CRC)according to the expression of PD-L1.METHODS This analysis included CRC patients who received bevacizumab plus FOLFOX or FOLFIRI as first-line therapy between June 24,2014 and February 28,2022,at Samsung Medical Center(Seoul,South Korea).Analysis of patient data included evaluation of PD-L1 expression by the combined positive score(CPS).We analyzed the efficacy of bevacizumab according to PD-L1 expression status in patients with CRC.RESULTS A total of 124 patients was included in this analysis.Almost all patients were treated with bevacizumab plus FOLFIRI or FOLFOX as the first-line chemotherapy.While 77%of patients received FOLFOX,23%received FOLFIRI as backbone first-line chemotherapy.The numbers of patients with a PD-L1 CPS of 1 or more,5 or more,or 10 or more were 105(85%),64(52%),and 32(26%),respectively.The results showed no significant difference in progression-free survival(PFS)and overall survival(OS)with bevacizumab treatment between patients with PDL1 CPS less than 1 and those with PD-L1 CPS of 1 or more(PD-L1<1%vs PD-L1≥1%;PFS:P=0.93,OS:P=0.33),between patients with PD-L1 CPS less than 5 and of 5 or more(PD-L1<5%vs PD-L1≥5%;PFS:P=0.409,OS:P=0.746),and between patients with PD-L1 CPS less than 10 and of 10 or more(PD-L1<10%vs PD-L1≥10%;PFS:P=0.529,OS:P=0.568).CONCLUSION Chemotherapy containing bevacizumab can be considered as first-line therapy in metastatic CRC irrespective of PD-L1 expression. 展开更多
关键词 BEVACIZUMAB Colorectal cancer programmed cell death ligand 1 expression First-line chemotherapy Metastatic colorectal cancer
下载PDF
Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma
7
作者 Hui Yang Guang-Ping Qiu +1 位作者 Jie Liu Tie-Quan Yang 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第11期4392-4401,共10页
BACKGROUND The combination of transarterial chemoembolization(TACE),lenvatinib,and programmed cell death 1(PD-1)inhibitor has been widely used in the treatment of advanced hepatocellular carcinoma(HCC)and has achieved... BACKGROUND The combination of transarterial chemoembolization(TACE),lenvatinib,and programmed cell death 1(PD-1)inhibitor has been widely used in the treatment of advanced hepatocellular carcinoma(HCC)and has achieved promising results.However,there are few studies comparing whether drug-eluting beads TACE(DTACE)can bring more survival benefits to patients with large HCC compared to conventional TACE(C-TACE)in this triplet therapy.AIM To compare the efficacy and adverse events(AEs)of triple therapy comprising DTACE,PD-1 inhibitors,and lenvatinib(D-TACE-P-L)and C-TACE,PD-1 inhibitors,and lenvatinib(C-TACE-P-L)in patients with large HCC(maximum diameter≥5 cm),and analyze the prognostic factors.METHODS Following a comprehensive review of our hospital’s medical records,this retrospective study included 104 patients:50 received D-TACE-P-L,and 54 received CTACE-P-L.We employed Kaplan-Meier estimation to assess the median progression-free survival(PFS)between the two groups,utilized Cox multivariate regression analysis to identify prognostic factors,and applied theχ2 test to evaluate AEs.RESULTS The objective response rate(ORR)and median PFS were significantly higher in the D-TACE-P-L group compared to the C-TACE-P-L group(ORR:66.0%vs 44.4%,P=0.027;median PFS:6.8 months vs 5.0 months,P=0.041).Cox regression analysis identified treatment option,portal vein tumor thrombus,and hepatic vein invasion as protective factors for PFS.AEs were comparable between the two CONCLUSION D-TACE-P-L may have significantly better PFS and ORR for large HCC,while exhibiting similar AEs to C-TACE-PL. 展开更多
关键词 Large hepatocellular carcinoma Conventional transarterial chemoembolization Drug-eluting beads transarterial chemoembolization programmed cell death 1 inhibitor Lenvatinib
下载PDF
Effectiveness and tolerability of programmed cell death protein-1 inhibitor+chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers
8
作者 Xiao-Min Zhang Ting Yang +5 位作者 Ying-Ying Xu Bao-Zhong Li Wei Shen Wen-Qing Hu Cai-Wen Yan Liang Zong 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第4期1613-1625,共13页
BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,i... BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,it is unclear whether this combination is superior to chemotherapy alone.AIM To assess the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer,gastroesophageal junction(GEJ)cancer,or oesophageal carcinoma.METHODS We searched the PubMed and Embase databases for studies that compared the efficacy and tolerance of PD-1 inhibitors in combination with chemotherapy vs chemotherapy alone in patients with advanced oesophageal or gastric cancer.We employed either random or fixed models to analyze the outcomes of each clinical trial,en-compassing data on overall survival(OS),progression-free survival(PFS),objective response rate,and adverse events(AEs).RESULTS Nine phase 3 clinical trials(7016 advanced oesophageal and gastric cancer patients)met the inclusion criteria.Our meta-analysis demonstrated that the pooled PD-1 inhibitor+chemotherapy group had a significantly longer OS than the chemotherapy-alone group[hazard ratio(HR)=0.76,95%confidence interval(CI):0.71-0.81];the pooled PFS result was consistent with that of OS(HR=0.67,95%CI:0.61-0.74).The count of patients achieving an objective response in the PD-1 inhibitor+chemotherapy group surpassed that of the chemotherapy-alone group[odds ratio(OR)=1.86,95%CI:1.59-2.18].AE incidence was also higher in the combination-therapy group than in the chemotherapy-alone group,regardless of whether≥grade 3 only(OR=1.30,95%CI:1.07-1.57)or all AE grades(OR=1.88,95%CI:1.39-2.54)were examined.We performed a subgroup analysis based on the programmed death-ligand 1(PD-L1)combined positive score(CPS)and noted extended OS and PFS durations within the CPS≥1,CPS≥5,and CPS≥10 subgroups of the PD-1 inhibitor+chemotherapy group.CONCLUSION In contrast to chemotherapy alone,the combination of PD-1 inhibitor and chemotherapy appears to present a more favorable option for initial or subsequent treatment in patients with gastric cancer,GEJ tumor,or oesophageal cancer.This holds true particularly for individuals with PD-L1 CPS scores of≥5 and≥10. 展开更多
关键词 programmed cell death protein-1 inhibitor CHEMOTHERAPY Oesophageal squamous cell carcinoma Gastric/gastroesophageal junction adenocarcinoma Overall survival Progression-free survival Objective response rate Adverse event
下载PDF
Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
9
作者 Shi-Qiong Zhou Peng Wan +3 位作者 Sen Zhang Yuan Ren Hong-Tao Li Qing-Hua Ke 《World Journal of Clinical Oncology》 2024年第7期859-866,共8页
BACKGROUND Pancreatic adenocarcinoma,a malignancy that arises in the cells of the pancreas,is a devastating disease with unclear etiology and often poor prognosis.Locally advanced pancreatic cancer,a stage where the t... BACKGROUND Pancreatic adenocarcinoma,a malignancy that arises in the cells of the pancreas,is a devastating disease with unclear etiology and often poor prognosis.Locally advanced pancreatic cancer,a stage where the tumor has grown significantly but has not yet spread to distant organs,presents unique challenges in treatment.This article aims to discuss the current strategies,challenges,and future directions in the management of locally advanced pancreatic adenocarcinoma(LAPC).AIM To investigate the feasibility and efficacy of programmed cell death 1(PD-1)inhibitor sintilimab plus concurrent chemoradiotherapy for LAPC.METHODS Eligible patients had LAPC,an Eastern cooperative oncology group performance status of 0 or 1,adequate organ and marrow functions,and no prior anticancer therapy.In the observation group,participants received intravenous sintilimab 200 mg once every 3 wk,and received concurrent chemoradiotherapy(concurrent conventional fractionated radiotherapy with doses planning target volume 50.4 Gy and gross tumor volume 60 Gy in 28 fractions and oral S-140 mg/m2 twice daily on days 1-14 of a 21-d cycle and intravenous gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-d cycle for eight cycles until disease progression,death,or unacceptable toxicity).In the control group,participants only received concurrent chemoradiotherapy.From April 2020 to November 2021,64 participants were finally enrolled with 34 in the observation group and 30 in the control group.RESULTS Thirty-four patients completed the scheduled course of chemoradiotherapy,while 32(94.1%)received sintilimab plus concurrent chemoradiotherapy with 2 patients discontinuing sintilimab in the observation group.Thirty patients completed the scheduled course of chemoradiotherapy in the control group.Based on the Response Evaluation Criteria in Solid Tumors guidelines,the analysis of the observation group revealed that a partial response was observed in 11 patients(32.4%),stable disease was evident in 19 patients(55.9%),and 4 patients(11.8%)experienced progressive disease;a partial response was observed in 6(20.0%)patients,stable disease in 18(60%),and progressive disease in 6(20%)in the control group.The major toxic effects were leukopenia and nausea.The incidence of severe adverse events(AEs)(grade 3 or 4)was 26.5%(9/34)in the observation group and 23.3%(7/30)in the control group.There were no treatment-related deaths.The observation group demonstrated a significantly longer median overall survival(22.1 mo compared to 15.8 mo)(P<0.05)and progression-free survival(12.2 mo vs 10.1 mo)(P<0.05)in comparison to the control group.The occurrence of severe AEs did not exhibit a statistically significant difference between the observation group and the control group(P>0.05).CONCLUSION Sintilimab plus concurrent chemoradiotherapy was effective and safe for LAPC patients,and warrants further investigation. 展开更多
关键词 IMMUNOTHERAPY Concurrent chemoradiotherapy Locally advanced pancreatic adenocarcinoma programmed cell death 1 Sintilimab
下载PDF
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma 被引量:3
10
作者 Yan-Yu Wang Xu Yang +12 位作者 Yun-Chao Wang Jun-Yu Long Hui-Shan Sun Yi-Ran Li Zi-Yu Xun Nan Zhang Jing-Nan Xue Cong Ning Jun-Wei Zhang Cheng-Pei Zhu Long-Hao Zhang Xiao-Bo Yang Hai-Tao Zhao 《World Journal of Gastroenterology》 SCIE CAS 2023年第10期1614-1626,共13页
BACKGROUND Programmed death receptor-1(PD-1)inhibitors have been approved as secondline treatment regimen in hepatocellular carcinoma(HCC),but it is still worth studying whether patients can benefit from PD-1 inhibito... BACKGROUND Programmed death receptor-1(PD-1)inhibitors have been approved as secondline treatment regimen in hepatocellular carcinoma(HCC),but it is still worth studying whether patients can benefit from PD-1 inhibitors as first-line drugs combined with targeted drugs and locoregional therapy.AIM To estimate the clinical outcome of transarterial chemoembolization(TACE)and lenvatinib plus PD-1 inhibitors for patients with unresectable HCC(uHCC).METHODS We carried out retrospective research of 65 patients with uHCC who were treated at Peking Union Medical College Hospital from September 2017 to February 2022.45 patients received the PD-1 inhibitors,lenvatinib,TACE(PD-1-Lenv-T)therapy,and 20 received the lenvatinib,TACE(Lenv-T)therapy.In terms of the dose of lenvatinib,8 mg was given orally for patients weighing less than 60 kg and 12 mg for those weighing more than 60 kg.Of the patients in the PD-1 inhibitor combination group,15 received Toripalimab,14 received Toripalimab,14 received Camrelizumab,4 received Pembrolizumab,9 received Sintilimab,and 2 received Nivolumab,1 with Tislelizumab.According to the investigators’assessment,TACE was performed every 4-6 wk when the patient had good hepatic function(Child-Pugh class A or B)until disease progression occurred.We evaluated the efficacy by the modified Response Evaluation Criteria in Solid Tumors(mRECIST criteria).We accessd the safety by the National Cancer Institute Common Terminology Criteria for Adverse Events,v 5.0.The key adverse events(AEs)after the initiation of combination therapy were observed.RESULTS Patients with uHCC who received PD-1-Lenv-T therapy(n=45)had a clearly longer overall survival than those who underwent Lenv-T therapy(n=20,26.8 vs 14.0 mo;P=0.027).The median progression-free survival time between the two treatment regimens was also measured{11.7 mo[95%confidence interval(CI):7.7-15.7]in the PD-1-Lenv-T group vs 8.5 mo(95%CI:3.0-13.9)in the Lenv-T group(P=0.028)}.The objective response rates of the PD-1-Lenv-T group and Lenv-T group were 44.4%and 20%(P=0.059)according to the mRECIST criteria,meanwhile the disease control rates were 93.3%and 64.0%(P=0.003),respectively.The type and frequency of AEs showed little distinction between patients received the two treatment regimens.CONCLUSION Our results suggest that the early combination of PD-1 inhibitors has manageable toxicity and hopeful efficacy in patients with uHCC. 展开更多
关键词 Lenvatinib programmed death receptor-1 inhibitor IMMUNOTHERAPY Hepatocellular carcinoma Transarterial chemoembolization Combination therapy
下载PDF
Expression characteristics of peripheral lymphocyte programmed death 1 and FoxP3+ Tregs in gastric cancer during surgery and chemotherapy
11
作者 Hao Li Guan-Mei Cao +4 位作者 Guo-Li Gu Song-Yan Li Yang Yan Ze Fu Xiao-Hui Du 《World Journal of Gastroenterology》 SCIE CAS 2023年第40期5582-5592,共11页
BACKGROUND Programmed death 1(PD-1)and CD4^(+)CD25^(+)FoxP3^(+)expression in peripheral blood T-cells has been previously reported in various types of cancer.However,the specific variation tendency during surgery and ... BACKGROUND Programmed death 1(PD-1)and CD4^(+)CD25^(+)FoxP3^(+)expression in peripheral blood T-cells has been previously reported in various types of cancer.However,the specific variation tendency during surgery and chemotherapy,as well as their relationship in gastric cancer patients,still remain unclear.Understanding this aspect may provide some novel insights for future studies on tumor recurrence and tumor immune escape,and also serve as a reference for determining the optimal timing and dose of clinical anti-PD-1 antibodies.AIM To observe and analyze the expression characteristics of peripheral lymphocyte PD-1 and FoxP3^(+)regulatory T cells(FoxP3^(+)Tregs)before and after surgery or chemotherapy in gastric cancer patients.METHODS Twenty-nine stomach cancer patients undergoing chemotherapy after a D2 gastrectomy provided 10 mL peripheral blood samples at each phase of the perioperative period and during chemotherapy.This study also included 29 agematched healthy donors as a control group.PD-1 expression was detected on lymphocytes,including CD4^(+)CD8^(+)CD45RO^(+),CD4^(+)CD45RO^(+),and CD8^(+)CD45RO^(+)lymphocytes as well as regulatory T cells.RESULTS We observed a significant increase of PD-1 expression on immune subsets and a larger number of FoxP3^(+)Tregs in gastric cancer patients(P<0.05).Following D2 gastrectomy,peripheral lymphocytes PD-1 expression and the number of FoxP3^(+)Tregs notably decrease(P<0.05).However,during postoperative chemotherapy,we only observed a decrease in PD-1 expression on lymphocytes in the CD8^(+)CD45RO^(+)and CD8^(+)CD45RO^(+)populations.Additionally,linear correlation analysis indicated a positive correlation between PD-1 expression and the number of CD4^(+)CD45RO^(+)FoxP3high activated Tregs(aTregs)on the total peripheral lymphocytes(r=0.5622,P<0.0001).CONCLUSION The observed alterations in PD-1 expression and the activation of regulatory T cells during gastric cancer treatment may offer novel insights for future investigations into tumor immune evasion and the clinical application of anti-PD-1 antibodies in gastric cancer. 展开更多
关键词 programmed death 1 Active regulatory T cells Stomach cancer Peripheral lymphocyte
下载PDF
Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
12
作者 Yong-Zhe Hou Qin Zhang +2 位作者 Hai Bai Tao Wu Ya-Jie Chen 《World Journal of Clinical Cases》 SCIE 2023年第7期1458-1466,共9页
Lymphoma,which is highly malignant,stems from lymph nodes and lymphoid tissue.Lymphoma cells express programmed death-ligand 1/2(PD-L1/PD-L2),which binds with programmed cell death 1 protein(PD-1)to establish inhibito... Lymphoma,which is highly malignant,stems from lymph nodes and lymphoid tissue.Lymphoma cells express programmed death-ligand 1/2(PD-L1/PD-L2),which binds with programmed cell death 1 protein(PD-1)to establish inhibitory signaling that impedes the normal function of T cells and allows tumor cells to escape immune system surveillance.Recently,immune checkpoint inhibitor immunotherapies such as PD-1 inhibitors(nivolumab and pembrolizumab)have been introduced into the lymphoma treatment algorithm and have shown remarkable clinical efficacy and greatly improve prognosis in lymphoma patients.Accordingly,the number of lymphoma patients who are seeking treatment with PD-1 inhibitors is growing annually,which results in an increasing number of patients developing immune-related adverse events(irAEs).The occurrence of irAEs inevitably affects the benefits provided by immunotherapy,particularly when PD-1 inhibitors are applied.However,the mechanisms and characteristics of irAEs induced by PD-1 inhibitors in lymphoma need further investigation.This review article summarizes the latest research advances in irAEs during treatment of lymphoma with PD-1 inhibitors.A comprehensive understanding of irAEs incurred in immunotherapy can help to achieve better efficacy with PD-1 inhibitors in lymphoma. 展开更多
关键词 LYMPHOMA programmed cell death 1 receptor Immune checkpoint inhibitors Immune-related adverse events Nivolumab Pembrolizumab
下载PDF
PD-1抑制剂联合安罗替尼治疗二线化疗失败的老年晚期非小细胞肺癌的效果 被引量:2
13
作者 张志胜 何学军 +3 位作者 张晶 纪晓燕 朱翔 包赟 《国际老年医学杂志》 2024年第2期187-192,共6页
目的 探究程序性死亡受体1(PD-1)抑制剂联合安罗替尼治疗二线化疗失败的老年晚期非小细胞肺癌(NSCLC)的临床疗效。方法 选取2019年1月—2021年4月泰州市第二人民医院收治的106例二线化疗失败的老年晚期NSCLC患者作为研究对象,按照随机... 目的 探究程序性死亡受体1(PD-1)抑制剂联合安罗替尼治疗二线化疗失败的老年晚期非小细胞肺癌(NSCLC)的临床疗效。方法 选取2019年1月—2021年4月泰州市第二人民医院收治的106例二线化疗失败的老年晚期NSCLC患者作为研究对象,按照随机数字表法分为单药组和联合组,各53例。单药组采用安罗替尼治疗,联合组采用PD-1抑制剂联合安罗替尼治疗。比较两组的疾病控制率、毒副反应发生情况、生存率、肿瘤标志物[细胞角蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原125(CA125)]、血管新生指标[血管内皮生长因子(VEGF)-A、VEGF受体2(VEGFR2)]、血清驱动蛋白超家族蛋白(KIF)C1、N-钙黏蛋白、生活质量核心量表(QLQ-C30)评分。结果 联合组疾病控制率高于单药组(P<0.05);治疗2个周期后,联合组血清CYFRA21-1、CA125、CEA、VEGF-A、VEGFR2、KIFC1及N-钙黏蛋白水平均低于单药组(P<0.05),QLQ-C30评分低于单药组(P<0.05);两组各毒副反应总发生率比较,差异均无统计学意义(P>0.05);Kaplan-Meier生存分析显示,联合组累积生存率高于单药组(P<0.05)。结论 PD-1抑制剂联合安罗替尼治疗二线化疗失败的老年晚期NSCLC效果显著,可有效调节血清KIFC1、N-钙黏蛋白表达,抑制VEGF-A、VEGFR2水平,降低肿瘤标志物水平,提高生活质量,延长生存时间,安全性高。 展开更多
关键词 程序性死亡受体1抑制剂 二线化疗失败 安罗替尼 非小细胞肺癌 生存期
下载PDF
PD-1单抗后线辅助治疗晚期结直肠癌患者对胃肠功能、肿瘤标志物的影响 被引量:1
14
作者 吴翔 岳春迪 李春芸 《临床和实验医学杂志》 2024年第9期941-945,共5页
目的分析程序性死亡受体-1(PD-1)单抗后线辅助治疗晚期结直肠癌患者对胃肠功能、肿瘤标志物的影响。方法前瞻性选取2020年1月至2023年1月海口市人民医院收治的105例晚期结直肠癌患者为研究对象,按照随机数字表法将患者分为对照组(n=50)... 目的分析程序性死亡受体-1(PD-1)单抗后线辅助治疗晚期结直肠癌患者对胃肠功能、肿瘤标志物的影响。方法前瞻性选取2020年1月至2023年1月海口市人民医院收治的105例晚期结直肠癌患者为研究对象,按照随机数字表法将患者分为对照组(n=50)、研究组(n=55)。对照组采用阿帕替尼治疗,研究组在对照组的基础上联合PD-1单抗后线治疗,3周为1个疗程,共治疗4个疗程。比较两组的临床疗效、胃肠功能改善时间,治疗前、治疗12周后的肿瘤标志物[癌胚抗原、糖类抗原(CA)72-4、CA199]、免疫功能(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))指标以及不良反应发生情况。结果治疗12周后,研究组的客观缓解率(ORR)、病情控制率(DCR)分别为78.33%、90.91%,均高于对照组(58.00%、70.00%),差异均有统计学意义(P<0.05)。研究组患者的首次排便时间、首次排气时间、肠鸣音消退时间分别为(51.50±5.02)、(35.52±4.25)、(44.28±4.80)d,均短于对照组[(69.37±6.40)、(50.63±5.10)、(53.50±6.15)d],差异均有统计学意义(P<0.05)。治疗12周后,研究组癌胚抗原、CA72-4、CA199水平分别为(12.57±1.64)ng/mL、(17.60±3.45)U/mL、(58.29±8.70)kU/L,均低于对照组[(17.24±2.50)ng/mL、(27.59±4.67)U/mL、(82.65±12.29)kU/L],差异均有统计学意义(P<0.05)。治疗12周后,研究组CD4^(+)、CD4^(+)/CD8^(+)水平分别为(21.42±3.54)%、0.73±0.30,均低于对照组[(28.39±4.38)%、1.12±0.41],CD8^(+)水平为(30.36±4.52)%,高于对照组[(25.71±3.30)%],差异均有统计学意义(P<0.05)。研究组的不良反应发生率为9.09%,稍低于对照组(16.00%),但两组比较差异无统计学意义(P>0.05)。结论通过PD-1单抗后线辅助治疗可有效改善晚期结直肠癌患者的临床疗效,效果明显,改善胃肠功能,降低肿瘤标志物指标水平,调节机体免疫功能,可为临床干预此病提供参考。 展开更多
关键词 结直肠肿瘤 晚期结直肠癌 程序性死亡受体-1单抗 胃肠功能 肿瘤标志物
下载PDF
血清细胞因子表达水平与非小细胞肺癌PD-1抑制剂疗效研究进展 被引量:1
15
作者 张鹏 李桂香 《兰州大学学报(医学版)》 2024年第1期82-86,共5页
程序性死亡受体-1(PD-1)/程序性死亡分子配体-1信号通路抑制剂激活机体免系统后产生的细胞因子在抗肿瘤细胞过程中发挥关键作用。本文回顾近年来接受PD-1抑制剂治疗的非小细胞肺癌患者血清细胞因子表达水平与临床获益的相关性研究,揭示... 程序性死亡受体-1(PD-1)/程序性死亡分子配体-1信号通路抑制剂激活机体免系统后产生的细胞因子在抗肿瘤细胞过程中发挥关键作用。本文回顾近年来接受PD-1抑制剂治疗的非小细胞肺癌患者血清细胞因子表达水平与临床获益的相关性研究,揭示非小细胞肺癌患者PD-1治疗前后白介素-6、白介素-8、肿瘤坏死因子、干扰素、白介素-17A等细胞因子水平变化,为寻找经济、便捷的PD-1抑制剂疗效生物标志物提供思路和线索。 展开更多
关键词 非小细胞肺癌 程序性死亡受体-1抑制剂 细胞因子 疗效预测
下载PDF
口蹄疫病毒感染后猪PD-1及其配体转录水平变化和免疫抑制机制分析
16
作者 岳锋 周娟娟 +4 位作者 朱艳平 郭东光 夏黎明 祝仰钊 王选年 《河南农业科学》 北大核心 2024年第8期126-132,共7页
研究猪感染口蹄疫病毒(Foot-and-mouth disease virus,FMDV)后程序性死亡受体-1(Programmed death-1,PD-1)及其配体(PD-L1、PD-L2),细胞因子[IL-2(Interleukin-2)、IL-10(Interleukin-10)、IFN-γ(Interferon-γ)]mRNA转录水平和外周血... 研究猪感染口蹄疫病毒(Foot-and-mouth disease virus,FMDV)后程序性死亡受体-1(Programmed death-1,PD-1)及其配体(PD-L1、PD-L2),细胞因子[IL-2(Interleukin-2)、IL-10(Interleukin-10)、IFN-γ(Interferon-γ)]mRNA转录水平和外周血单个核细胞(Peripheral blood mononuclear cells,PBMCs)增殖能力,探讨PD-1/PD-Ls通路在FMDV引起免疫抑制过程中的作用机制。结果表明,猪感染FMDV后3、7、14、17 d,PD-1的mRNA转录水平显著或极显著升高,感染后7 d达到峰值,之后逐渐降低;感染FMDV后3 d和7 d,PD-L1的mRNA转录水平极显著升高;感染FMDV后3 d,PD-L2的mRNA转录水平显著升高。感染FMDV后3、7 d,IL-2的mRNA转录水平显著下降;感染FMDV后1、3 d,IFN-γ的mRNA转录水平极显著下降,IL-2和IFN-γ的mRNA转录水平与PD-1及其配体mRNA转录水平变化趋势相反;感染FMDV后3、7、14 d,IL-10的mRNA转录水平显著或极显著升高,与PD-1及其配体mRNA转录水平变化趋势相同。感染FMDV后,全血中FMDV的病毒载量随着感染后时间的推进逐渐升高,感染后7 d达到峰值,与PD-1及其配体mRNA转录水平变化趋势总体上相同。感染后7 d,PBMCs的增殖能力明显降低。综上,FMDV感染猪后,总体上上调了PD-1及其配体的mRNA转录水平,是FMDV感染引起机体免疫抑制的重要致病机制。 展开更多
关键词 口蹄疫病毒 程序性死亡受体-1 程序性死亡受体配体-1 转录水平 免疫抑制机制
下载PDF
PD-1在原发性肝细胞癌组织中的表达及意义
17
作者 李素燕 安黎云 +1 位作者 张会峰 王缚鲲 《药学研究》 CAS 2024年第9期913-917,共5页
目的旨在探讨程序性死亡受体-1(PD-1)在原发性肝细胞癌(HCC)组织中的表达及意义。方法回顾性分析2020年5月—2022年5月于联勤保障部队第980(白求恩国际和平)医院接受诊治的HCC患者70例,所有患者均经过影像学及病理学证实为HCC。术中取... 目的旨在探讨程序性死亡受体-1(PD-1)在原发性肝细胞癌(HCC)组织中的表达及意义。方法回顾性分析2020年5月—2022年5月于联勤保障部队第980(白求恩国际和平)医院接受诊治的HCC患者70例,所有患者均经过影像学及病理学证实为HCC。术中取肝癌原发病灶处癌组织制作为肝癌标本,取肝癌原发病灶5 cm以外的肝组织作为癌旁正常肝组织标本,对所有标本进行切片处理,通过免疫组化、Western blotting等方法,检测标本组织中PD-1的表达情况;分析癌组织、癌旁组织以及不同分化程度的HCC PD-1的表达情况;分析不同病理特征(年龄、性别、肿瘤大小、HBV阳性与否、是否转移、是否合并腹水)对PD-1表达情况的影响。结果癌组织的PD-1表达水平明显高于癌旁组织,差异均具有统计学意义(P<0.05);中分化型HCC PD-1表达水平明显高于高分化及低分化型HCC,差异均具有统计学意义(P<0.05);高分化型与低分化型相比,差异不具有统计学意义(P>0.05);PD-1阳性表达与HCC患者年龄、性别、HBV是否阳性无关,差异不具有统计学意义(P>0.05);PD-1阳性表达与肿瘤大小、肿瘤是否转移以及有无腹水有关,差异具有统计学意义(P<0.05);肿瘤直径>6 cm、肿瘤发生转移以及合并腹水的HCC患者PD-1阳性表达率较高。另外,通过qPCR及Western blotting测定发现PD-1在Ⅲ~Ⅳ期肝癌表达高于Ⅰ~Ⅱ期肝癌。结论PD-1在癌组织中以及中分化型HCC表达水平较高;且肿瘤分期越高,直径越大,合并转移及腹水时,PD-1表达水平高。因此PD-1有望成为判断HCC分期以及预后的指标之一,为HCC的诊断及治疗提供新策略。 展开更多
关键词 原发性肝细胞癌 程序性死亡受体-1 程序性死亡配体-1 免疫抑制
下载PDF
ITP患者PD-1/PD-L1表达特点及其在Treg与Breg细胞之间的相互作用机制分析
18
作者 许腾 崔彦杰 +2 位作者 李智伟 刘红春 郝立君 《西部医学》 2024年第4期608-613,共6页
目的探讨原发免疫性血小板减少症(ITP)患者细胞程序性死亡受体-1(PD-1)/细胞程序性死亡配体1(PD-L1)表达特点及其在调节性T细胞(Treg)、调节性B细胞(Breg)间的相互作用。方法选取2018年12月—2022年1月在我院治疗的ITP患者106例作为观察... 目的探讨原发免疫性血小板减少症(ITP)患者细胞程序性死亡受体-1(PD-1)/细胞程序性死亡配体1(PD-L1)表达特点及其在调节性T细胞(Treg)、调节性B细胞(Breg)间的相互作用。方法选取2018年12月—2022年1月在我院治疗的ITP患者106例作为观察组,其中轻度患者32例,中度患者44例,重度患者30例。同时选取同期健康志愿者100例作为对照组。检测两组Treg细胞百分比、Breg细胞百分比、Treg细胞表面PD-1阳性率、Breg细胞表面PD-L1阳性率等,同时分析观察组不同病情程度患者各指标差异。结果观察组Breg细胞百分比、Treg细胞百分比、TGF-β、IL-10和IL-4水平均明显低于对照组(P<0.05);观察组Treg细胞表面PD-1阳性率、Breg细胞表面PD-L1阳性率、可溶性程序性细胞死亡蛋白-1(sPD-1)和IL-17水平均明显高于对照组(均P<0.05);两组可溶性程序性细胞死亡蛋白配体-1(sPD-L1)水平比较差异无统计学意义(P>0.05)。观察组重度患者Breg细胞百分比、Treg细胞百分比均明显低于轻度和中度患者(均P<0.05),而Treg细胞表面PD-1阳性率、Breg细胞表面PD-L1阳性率均明显高于轻度和中度患者(均P<0.05)。Treg细胞表面PD-1阳性率与Breg细胞表面PD-L1阳性率呈正相关(r=0.446,P<0.05)。观察组治疗后Breg细胞百分比、Treg细胞百分比、TGF-β、IL-10和IL-4水平有所升高(P<0.05),而Treg细胞表面PD-1阳性率、Breg细胞表面PD-L1阳性率、sPD-1和IL-17水平有所降低(P<0.05),治疗前后sPD-L1水平比较差异无统计学意义(P>0.05)。结论ITP患者Treg细胞表面PD-1和Breg细胞表面PD-L1阳性率明显升高,与患者病情严重程度呈正相关,同时Treg细胞表面PD-1和Breg细胞表面PD-L1表达之间存在相关性。 展开更多
关键词 原发免疫性血小板减少症 细胞程序性死亡受体-1 细胞程序性死亡配体1 调节性T细胞 调节性B细胞
下载PDF
血清中PD-L1含量与胃癌病人预后的关系
19
作者 陈长强 严晓伟 +3 位作者 胡皆乐 包皙婷 项明 姜松耀 《外科理论与实践》 2024年第3期230-235,共6页
目的:分析胃癌病人血清中程序性死亡配体1(programmed death-ligand 1,PD-L1)含量及其与肿瘤分期和预后的关系。方法:收集我院2018年8月至2019年12月60例胃癌病人血清,15例健康成人血清作为对照,通过酶联免疫吸附试验(ELISA)检测血清PD... 目的:分析胃癌病人血清中程序性死亡配体1(programmed death-ligand 1,PD-L1)含量及其与肿瘤分期和预后的关系。方法:收集我院2018年8月至2019年12月60例胃癌病人血清,15例健康成人血清作为对照,通过酶联免疫吸附试验(ELISA)检测血清PD-L1的含量,比较胃癌病人与健康成人血清PD-L1含量的差异,分析胃癌病人血清PD-L1的含量与病期及预后的关系。免疫组织化学检测肿瘤组织内PD-L1的表达情况,并分析其与血清中PD-L1含量的相关性。结果:胃癌组血清中PD-L1的含量明显高于对照组。Ⅲ、Ⅳ期胃癌病人血清PD-L1含量明显高于Ⅰ、Ⅱ期胃癌病人。胃癌病人合并腹膜转移者血清PD-L1含量明显升高,提示预后不良。生存分析显示,血清PD-L1含量高的胃癌病人生存期明显短于低者。检测肿瘤组织标本中PD-L1的表达水平,发现其与血清中PD-L1含量无明显相关性。结论:胃癌病人血清中PD-L1含量高于健康成人。随病期进展逐渐升高。胃癌伴腹膜转移的病人血清中PD-L1升高明显。血清中PD-L1含量与肿瘤组织中的PD-L1表达不相关。 展开更多
关键词 胃癌 程序性死亡配体1 血清
下载PDF
炎调方通过PD-1/PD-L1通路抑制脓毒症大鼠T淋巴细胞衰竭的实验研究
20
作者 王文清 王庆 +1 位作者 熊旭东 方荣 《河北医药》 CAS 2024年第10期1463-1467,共5页
目的研究炎调方对脓毒症大鼠T淋巴细胞及T淋巴细胞表面表面程序性死亡蛋白(PD-1)、程序性死亡蛋白配体(PD-L1)表达的影响。方法SD大鼠(雄性)分为正常组、假手术组、模型组和炎调方组。盲肠结扎穿孔(CLP)制备脓毒症大鼠模型,于造模后12... 目的研究炎调方对脓毒症大鼠T淋巴细胞及T淋巴细胞表面表面程序性死亡蛋白(PD-1)、程序性死亡蛋白配体(PD-L1)表达的影响。方法SD大鼠(雄性)分为正常组、假手术组、模型组和炎调方组。盲肠结扎穿孔(CLP)制备脓毒症大鼠模型,于造模后12、24、48、72 h采集外周血处死大鼠(每个时间点各5只大鼠),采用流式细胞分析法测定CD3^(+)、CD4^(+)、CD8^(+)比例;双抗体夹心酶联免疫吸附法(ELISA)测定CD4^(+)及CD8^(+)表面PD-1、PD-L1表达水平。结果白介素-6(IL-6)在脓毒症模型组12 h分泌达到高峰后逐渐下降,降钙素原(PCT)在模型组24 h达到高峰后逐渐下降;炎调方组在12 h降低IL-6的水平(P<0.05),24 h时明显降低IL-6、PCT的水平(P<0.01)。模型组CD3^(+)、CD4^(+)、CD8^(+)比例早期分泌开始减少,48 h分泌达最低点(P<0.01);炎调方组在48 h时可升高CD3^(+)、CD4^(+)、CD8^(+)比例,提高CD4^(+)/CD8^(+)的比值而具体调节T细胞活化和增殖的功能。模型组CD4^(+)、CD8^(+)表面PD-1、PD-L1表达水平早期24 h即表达增多(P<0.01),72 h表达最多;炎调方组24 h时即可抑制PD-1、PD-L1的表达水平而具体改善T细胞衰竭的作用。CD4^(+)的比例与CD4^(+)表面PD-1、PD-L1的表达呈负相关(P<0.01);CD8^(+)比例与CD8^(+)表面PD-1、PD-L1的表达呈负相关(P<0.01)。结论脓毒症早期48 h内即出现了T细胞活化和增殖的功能衰竭引起的T细胞免疫抑制。炎调方能在脓毒症早期改善T细胞活化和增殖的功能,其机制可能与抑制PD-1/P-L1通路有关。 展开更多
关键词 炎调方 脓毒症T淋巴细胞衰竭 pd-1/pd-L1通路
下载PDF
上一页 1 2 122 下一页 到第
使用帮助 返回顶部